Search

EHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding

Jan 15 2020 Posted in Meeting reports

Meeting chairs, Carlo Balduini and Anna Falanga

The meeting was well attended by more than 100 participants coming from over 20 different countries

Delegate: Great meeting.

EHA Statement of Solidarity with Ukraine

Mar 01 2022 Posted in EHA's actions for Ukraine

The European Hematology Association (EHA) is deeply concerned about the situation in Ukraine, the plight of the civilian population, and the damage to healthcare infrastructures.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Jun 11 2016 Posted in Press releases

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Stem Cells

Mission:

The goal of the SWG on Stem Cells is to bring together researchers, biologists and clinicians involved in stem cell research to share their recent advances in the field, as well as to train new junior members.